Novo Holdings, the company behind the popular weight-loss drugs Ozempic and Wegovy, is pouring millions into developing a cutting-edge quantum technology hub in Denmark. This DKK 1.4 billion (€188 million) investment aims to foster a cluster of innovative startups with a focus on harnessing quantum computing's potential.
Quantum computers, with their ability to perform complex calculations in dramatically reduced timeframes, hold the promise of accelerating drug discovery and revolutionizing other aspects of life sciences. Novo Holdings, the parent company of Europe's most valuable firm, Novo Nordisk, is positioning itself at the forefront of this technological revolution.
"The rapid development of quantum technologies, particularly in the Nordic region, presents a unique opportunity," states the company's press release.
This initiative aligns with Novo Group's existing commitment to the field. The Novo Nordisk Foundation has established the Quantum Computing Programme (NQCP), dedicated to developing a fully functional, broadly applicable quantum computer. Additionally, the Novo Group founded The Quantum Foundry, a company specializing in the development of advanced quantum materials and chips.
The Danish government is also a significant contributor, investing the equivalent of €160 million in quantum technology research. This combined public and private support solidifies Denmark's status as a global leader in per capita quantum technology investment.
.jpg)
